Target family: Bombesin receptors (type: gpcr)
Target: BB<sub>2</sub> receptor

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: BAY86-7548 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.
Published in: Clin Cancer Res

Ligand: BAY86-7548 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Radiolabeled Bombesin Analogs.
Published in: Cancers (Basel)

Ligand: BAY86-7548 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Published in: Nuklearmedizin

Ligand: BAY86-7548 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: BAY86-7548 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.
Published in: Eur J Nucl Med Mol Imaging

Ligand: bantag-1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Comparative Pharmacology of Bombesin Receptor Subtype-3, Nonpeptide Agonist MK-5046, a Universal Peptide Agonist, and Peptide Antagonist Bantag-1 for Human Bombesin Receptors.
Published in: Pharmacol Exp Therap

Ligand: bantag-1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.
Published in: Cell Metab

Ligand: AM-37 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pKi
Reference (Journal): AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.
Published in: Front Endocrinol (Lausanne)

Ligand: Ac-GRP-(20-26)-methylester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Carboxyl-terminal modification of a gastrin releasing peptide derivative generates potent antagonists.
Published in: J Biol Chem

Ligand: Ac-GRP-(20-26)-methylester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [(3-Ph-Pr6), His7,D-Ala11,D-Pro13,ψ13-14),Phe14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 12 pIC50
Reference (Journal): Development of potent gastrin-releasing peptide antagonists having a D-Pro-psi(CH2NH)-Phe-NH2 C terminus.
Published in: Proc Natl Acad Sci USA

Ligand: [(3-Ph-Pr6), His7,D-Ala11,D-Pro13,ψ13-14),Phe14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [(3-Ph-Pr6), His7,D-Ala11,D-Pro13,ψ13-14),Phe14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pIC50
Reference (Journal): Development of potent gastrin-releasing peptide antagonists having a D-Pro-psi(CH2NH)-Phe-NH2 C terminus.
Published in: Proc Natl Acad Sci USA